NKp30/NCR3 Antibody [Alexa Fluor® 700]

• Reactivity: Hu
• Applications: WB
• Clonality: Polyclonal
• Host: Goat
• Conjugate: Alexa Fluor 700

NKp30/NCR3 Antibody [Alexa Fluor® 700] Summary

• Immunogen: Mouse myeloma cell line NS0-derived recombinant human NKp30/NCR3
  Leu19-Thr138
  Accession # Q05D23
• Specificity: Detects human NKp30/NCR3 in direct ELISAs and Western blots. In direct ELISAs and Western blots, less than 5% cross‑reactivity with recombinant human (rh) NKp80, rhNKp44 and rhNKp46 is observed.
• Isotype: IgG
• Clonality: Polyclonal
• Host: Goat
• Purity Statement: Antigen Affinity-purified

Applications/Dilutions

• Dilutions:
  • Western Blot

Packaging, Storage & Formulations

• Storage: Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 °C as supplied
• Buffer: Supplied 0.2mg/ml in 1X PBS with RDF1 and 0.09% Sodium Azide

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for NKp30/NCR3 Antibody [Alexa Fluor® 700]

• Activating natural killer receptor p30
• CD337 antigen
• CD337
• CD337activating NK-A1 receptor
• LY117,1C7NK-p30
• lymphocyte antigen 117
• natural cytotoxicity triggering receptor 3
• Natural killer cell p30-related protein
• NCR3
• NKp30
• NKp30MALS

Background

NKp30, along with NKp44 and NKp46, constitute a group of receptors termed “Natural Cytotoxicity Receptors” (1). These receptors play a major role in triggering NK‑mediated killing of most tumor cells lines. NKp30 is a type I transmembrane protein having a single extracellular V-like immunoglobulin domain (2). A physical association with the ITAM-bearing accessory protein, CD3 zeta , occurs via a charged residue in the NKp30 transmembrane domain. Ligation of NKp30 with a specific antibody results in phosphorylation of CD3 zeta (3). NKp30 is expressed on both resting and activated NK cells of the CD56^dim, CD16⁺ subset that account for more that 85% of NK cells found in peripheral blood and spleen (4). NKp30 is absent from the CD56^bright, CD16^- subset that constitutes the majority of NK cells in lymph node and tonsil, however, its expression is up‑regulated in these cells upon IL-2 activation (4). Studies with neutralizing antibodies reveal that NKp30 is partially responsible for triggering lytic activity against several tumor cell types and that it is the main receptor responsible for NK‑mediated lysis of immature dendritic cells (2, 5). The ligand(s) recognized by NKp30 has not been described.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.